text_1: Panel favors continuation of ArQule liver cancer drug study.
text_2: ArQule Inc said an independent committee recommended a late-stage study of the company’s cancer drug continue with a lower dose, months after liver cancer patients who received a greater dose showed a higher incidence of a blood disorder.